Abstract: Administration of an antibody that specifically binds IL-1? is useful for treating cachexia and increasing the lifespan of a subject suffering from cachexia.

Abstract: The present invention relates to methods for treating melanoma and other indications by inhibiting leptin activity.

Abstract: Disclosed is to identify a target molecule that is involved in Dkk1-induced hyperproliferation of tumor cells to provide a novel antitumor agent. Cytoskeleton-associated protein 4 (CKAP4) specifically regulates the hyperproliferation effects that are induced by dickkopf-related protein 1 (Dkk1), and proliferation of tumor cells can be suppressed by inhibiting expression or function of CKAP4 in the tumor cells.

Abstract: A method of managing pain in an individual including the following steps: providing an individual in need of pain management; administering an anti-P2X7 receptor antibody to the individual; thereby managing pain in the individual.

Abstract: Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.

Abstract: Anti-SIRP? antibodies, including multi-specific anti-SIRP? antibodies, are provided, as are related compositions and methods. The antibodies of the disclosure bind to SIRP? and can block the interaction of CD47 on one cell with SIRP? on a phagocytic cell. The subject anti-SIRP? antibodies find use in various therapeutic methods. Embodiments of the disclosure include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the anti-SIRP? antibodies; and cell lines that produce the antibodies. Also provided are amino acid sequences of exemplary anti-SIRP? antibodies.

Abstract: The present disclosure relates to the treatment of chronic lymphocytic leukemia. Monoclonal antibody XmAb5574 is efficacious when administered to patient at certain dosage regimens.

Abstract: The invention relates to new anti-hCTLA-4 antibodies that bind to a different epitope than prior art anti-CTLA4 antibodies, methods to produce these antibodies and therapeutic and diagnostic uses of these antibodies. These antibodies show a similar affinity for the CTLA4 antigen and they are also able to block the binding of CTLA4 to CD80 and/or CD86.

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor-infiltrating immune cells in a tumor sample obtained from the patient) and/or based on the determination of a tumor sample subtype.

Abstract: To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.

Abstract: Antibody drug conjugates (ADC's) that bind to FLT3 protein and variants thereof are described herein. FLT3 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.

Abstract: The present disclosure relates, in general, to methods of treating or preventing post-prandial hypoglycemia after gastric bypass surgery using a negative modulator antibody that binds to the insulin receptor and modulates the action of insulin at the insulin receptor.

Abstract: The present invention is directed to methods of preparing a conjugate of a cell-binding agent and a drug (such as a cytotoxic compound). The methods comprise the use of an imine reactive compound to enable efficient conjugations of cytotoxic compounds with cell binding agents.

Abstract: The present application discloses variants of Pertuzumab. In particular, it discloses: an unpaired cysteine variant comprising Cys23/Cys88 unpaired cysteines in one or both variable light domains of Pertuzumab, an afucosylated variant of Pertuzumab, a low-molecular-weight-species (LMWS) of Pertuzumab, and a high-molecular-weight-species (HMWS) or Pertuzumab. The application further discloses the isolated variants, compositions, pharmaceutical compositions, and articles of manufacture comprising the variants, as well as methods of making and characterizing the variants and compositions thereof.

Abstract: The present application discloses variants of Pertuzumab. In particular, it discloses: an unpaired cysteine variant comprising Cys23/Cys88 unpaired cysteines in one or both variable light domains of Pertuzumab, an afucosylated variant of Pertuzumab, a low-molecular-weight-species (LMWS) of Pertuzumab, and a high-molecular-weight-species (HMWS) or Pertuzumab. The application further discloses the isolated variants, compositions, pharmaceutical compositions, and articles of manufacture comprising the variants, as well as methods of making and characterizing the variants and compositions thereof.

Abstract: The present application discloses variants of Pertuzumab. In particular, it discloses: an unpaired cysteine variant comprising Cys23/Cys88 unpaired cysteines in one or both variable light domains of Pertuzumab, an afucosylated variant of Pertuzumab, a low-molecular-weight-species (LMWS) of Pertuzumab, and a high-molecular-weight-species (HMWS) or Pertuzumab. The application further discloses the isolated variants, compositions, pharmaceutical compositions, and articles of manufacture comprising the variants, as well as methods of making and characterizing the variants and compositions thereof.

Abstract: Disclosed herein are methods and compositions related to single chain antibody fragments which specifically bind sialyl-Tn epitope of tumor-associated glycoprotein 72 (TAG-72).

Abstract: Plasma kallikrein binding proteins and methods of using such proteins are described.

Abstract: Plasma kallikrein binding proteins and methods of using such proteins are described.

Abstract: Plasma kallikrein binding proteins and methods of using such proteins are described.

Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of factor B antagonists.

Abstract: The present invention describes novel immunoglobulin compositions that co-engage at least two antigens, e.g. a first and second antigen, or, as outlined herein, three or four antigens can be bound, in some of the scaffold formats described herein. First and second antigens of the invention are herein referred to as antigen-1 and antigen-2 respectively (or antigen-3 and antigen-4, if applicable. As outlined herein, a number of different formats can be used, with some scaffolds relying combinations of monovalent and bivalent bindings.

Abstract: Provided is a method for producing a short-chain peptide-immobilized carrier that maintains a secondary structure of a short-chain peptide, the method including a step of preparing an alcohol solution containing an alcohol solvent, and a short-chain peptide having a plurality of immobilizing functional groups, the short-chain peptide having a secondary structure induced in the alcohol solvent; and a step of bringing a carrier coupled with a spacer having a reactive group that reacts with the immobilizing functional group, into contact with the alcohol solution, and thereby immobilizing the short-chain peptide to the spacer.

Abstract: Provided is a cellulose acetate powder that makes it possible to reduce the formation of spotty patches on a formed article of the cellulose acetate and prevent lowering of the production process passability of the formed article. A cellulose acetate powder includes cellulose acetate having an acetylation degree of 53 to 56% and a 6% viscosity of 30 to 200 mPa·s. In the cellulose acetate powder, a cumulative pore volume is not less than 0.200 ml/g; a proportion of particles having a particle diameter of not less than 500 ?m is not higher than 40%; and an angle of repose is not greater than 51°.

Abstract: Disclosed are methods relating to an extruded pregelatinized, partially hydrolyzed starch prepared by mixing at least water, non-pregelatinized starch, and acid to form a starch precursor. The acid can be a weak acid that substantially avoids chelating calcium ions or a strong acid in a small amount. In the method, pregelatinization and acid-modification of the starch precursor occurs in one step in an extruder. Also disclosed are methods of preparing board using the starch prepared according to the methods, as well as starches and boards prepared by various methods of the invention.

Abstract: A process for the isolation of modified polysaccharide product from potato, in particular a polysaccharide product that can be used as an immunomodulatory is described. More particularly, the extraction and modification of a rhamnogalacturonan I(RG-1) fragment product from a potato using a defined process, and the use of this product to provide immunomodulatory activity to a subject.

Abstract: The invention relates to a biosourced polymer obtained by dual chemical functionalization of chitosan, usable for catalytic carbonation of cyclic ethers by means of carbon dioxide, and a binder composition for creating layers and/or coatings for road construction and/or civil engineering, marking materials, or sealing or insulation materials. Said composition contains a polyhydroxyurethane polymer binder resulting from the reaction of at least one polyamine with at least one polycyclocarbonate. Said polycyclocarbonate was obtained by carbonating a (cyclic) poly(ether) with carbon dioxide catalyzed by said biosourced polymer.

Abstract: The present invention provides a modified conjugated diene-based polymer, wherein the Mooney stress-relaxation rate measured at 110° C. is 0.45 or less, and the modification percentage is 75% by mass or more.

Abstract: The present invention provides a catalyst composition including a functionalizing agent of the following Formula 1 together with a rare earth metal compound, an alkylating agent, and a halogen compound, having good catalytic activity and polymerization reactivity and useful for the preparation of a conjugated diene-based polymer having high linearity and excellent processability, and a conjugated diene-based polymer prepared using the catalyst composition. (X1)a—N—(X2)3-a??[Formula 1] In Formula 1, a, X1, and X2 are the same as defined in the disclosure.

Abstract: The present invention provides a method for preparing a polyolefin having a broad molecular weight distribution. More specifically, the present invention provides a method for preparing a polyolefin having a broad molecular weight distribution and an ultra-high molecular weight in which an organometallic complex containing a specific Ti—Al complex structure is used as a molecular weight controller (i.e., molecular weight enhance) in the polymerization of an olefin monomer, thereby enabling both solution polymerization and slurry polymerization, particularly enabling the molecular weight distribution to be more readily and effectively controlled.

Abstract: This invention relates to compositions and methods for improving the impact properties of polymer-matrix composites and to improving the adhesion of resin compositions to substrate materials. More particularly, the invention relates to compositions and methods for improving the impact properties of ring opening metathesis polymerization (ROMP) polymer-matrix composites and to improving the adhesion of ROMP compositions to substrate materials using adhesion promoters containing at least two isocyanate groups and functional elastomers comprising a maleic anhydride grafted styrene-ethylene/butylene-styrene hydrogenated copolymer in a resin composition. The polymer products produced via ROMP reactions of the invention may be utilized for a wide range of materials and composite applications. The invention has utility in the fields of polymer and materials chemistry and manufacture.

Abstract: A precatalyst for the polymerization of ?-olefins, having the formula FeuMalcvXw(LA)y(LB)z wherein: Malc is an alkali metal and/or an alkaline-earth metal. X is an anion; LA is a Lewis acid; LB is a Lewis base; u is between 0.001 and 10; v is an integer ?1; w is between 1 and 20; y is between 0 and 10; z is between 0 and 10.

Abstract: Disclosed herein are methods of preparing a polymeric latex as the intermediary of a polymerization process. The disclosed methods further provide treatments for preventing biological growth on latex during storage extended storage at elevated temperatures.

Abstract: The invention provides an acrylic resin-based transparent substrate having an alignment layer spread thereon, wherein the photo-alignment layer and the substrate are kept tightly bonded to each other. The invention also provides a layered body having an acrylic resin-containing transparent substrate and, as formed on one surface of the transparent substrate by spreading and bonding thereto, a photo-alignment layer containing photo-responsive molecules capable of responding to light. According to the invention, there can be provided an acrylic resin-based transparent substrate having on the surface thereof, a photo-alignment layer having excellent adhesion force and containing photo-responsive molecules capable of responding to light.

Abstract: The disclosure relates to compositions containing 1,1-disubstituted alkene compounds capable of preparing polymers having glass transition temperatures above room temperature. The present teaching also relates to polymers prepared 1,1-disubstituted alkene compounds which exhibit glass transition temperatures of 60° C. The disclosure also relate to methods for enhancing the glass transition temperatures of polymers prepared from 1,1-disubstituted alkene compounds.

Abstract: The invention describes a process for producing a diene polymer, the process including the following steps in this order i) polymerizing one or more diene monomers in the presence of a catalyst composition to give a reaction mixture; ii) adding to the reaction mixture one or more alkoxysilane compounds; iii) adding S2Cl2, SCl2, SOCl2, S2Br2, SOBr2 or a mixture thereof to the reaction mixture; and iv) optionally adding a protic agent to the reaction mixture so as to deactivate the catalyst. The invention further includes polymers that are obtainable according to this process, as well as products including the polymer.

Abstract: Provided is an apparatus for preparing polybutadiene which may improve productivity by minimizing a plugging phenomenon occurred during the preparation of polybutadiene and increasing a conversion rate. The apparatus for preparing polybutadiene includes two first polymerization reactors arranged in parallel to reduce the plugging phenomenon in which butadiene (reaction raw material), a polymerization catalyst, and a solvent are respectively supplied and polymerized, at least one second polymerization reactor arranged in series with the first polymerization reactors in which a first polymerization solution containing a butadiene polymer discharged from the first polymerization reactors is supplied and a butadiene polymerization reaction is performed, and one or more condensers which condense gases discharged from the first polymerization reactors and the second polymerization reactor and supply a condensate to the first polymerization reactors and/or the second polymerization reactor.

Abstract: The present invention relates to a neodymium compound represented by Formula 1 and a catalyst for diene polymerization including the same.

Abstract: The present disclosure concerns a bulk polymerization process for the preparation of high heat performance copolymer resins with a reduced amount of oligomer byproduct. The method can comprise isolating oligomer byproduct and introducing the oligomer byproduct into the reactant mixture for the bulk polymerization process.

Abstract: The present invention provides a method for preparing a superabsorbent polymer, the method comprising the steps of: forming a function gel polymer by cross-linked polymerization of a monomer mixture under the presence of an internal cross-linking agent, the monomer mixture including a water-soluble ethylene-based unsaturated monomer having an acid group at least part of which is neutralized, a carbonate, a volatile organic solvent, a surfactant, and a bubble promoting agent; forming a base resin powder by drying, grinding, and classifying the function gel polymer; and forming a surface cross-linked layer by additional cross-linking of the surface of the base resin powder under the presence of a surface cross-linking agent. The method for preparing a superabsorbent polymer may provide a superabsorbent polymer which has a porous structure, thereby exhibiting an excellent absorption rate while exhibiting excellent gel strength.

Abstract: Polymer/copper combinations that can selectively target and kill cancer cells are described. Materials can include the reaction product of a biocompatible hydrophilic polymer and pyridine-2-thiol containing monomer. The copolymer reaction product can include pyridine-2-thiol side groups pendant to the backbone via a disulfide linkage. The hydrophilic component can form the polymer backbone and/or can form hydrophilic pendant groups off of the backbone. Copper ions can be associated with the copolymer.

Abstract: Provided are a curable composition for imprints which is capable of both improving releasability and suppressing occurrence of waviness during etching, as well as a cured product, a pattern forming method, a lithography method, a pattern, and a lithography mask, each of which uses the curable composition for imprints. The curable composition for imprints includes a monofunctional polymerizable compound, a polyfunctional polymerizable compound containing at least one of an alicyclic structure or an aromatic ring structure and having a viscosity at 25° C. of 150 mPa·s or less, and a photopolymerization initiator, in which the monofunctional polymerizable compound is contained in an amount of 5 to 30 mass % with respect to the total polymerizable compound in the curable composition for imprints, and the cured film of the curable composition for imprints has a modulus of elasticity of 3.5 GPa or less and a glass transition temperature of 90° C. or higher.

Abstract: To optimize the primary particle size of a modified PTFE fine powder to shorten the sintering time during the extrusion molding. A modified polytetrafluoroethylene fine powder which is a fine powder of a non-melt-processable modified polytetrafluoroethylene comprising units derived from tetrafluoroethylene, units derived from hexafluoropropylene, units derived from a perfluoro(alkyl vinyl ether) represented by CF2?CFO—CnF2n+1 (n is an integer of from 1 to 6) and units derived from a (perfluoalkyl)ethylene represented by CH2?CH—CmF2m+1 (m is an integer of from 3 to 7).

Abstract: Provided are polymer compositions made by a process comprising: (a) providing a first reactive composition containing: (i) a polymerization initiator that is capable, upon a first activation, of forming two or more free radical groups, at least one of which is further activatable by subsequent activation; (ii) one or more ethylenically unsaturated compounds; and (iii) a crosslinker; (b) subjecting the first reactive composition to a first activation step such that the first reactive composition polymerizes therein to form a crosslinked substrate network containing a covalently bound activatable free radical initiator, (c) combining the crosslinked substrate network with a second reactive composition containing one or more ethylenically unsaturated compounds; and (d) activating the covalently bound activatable free radical initiator of the crosslinked substrate network such that the second reactive composition polymerizes therein with the crosslinked substrate network to form a grafted polymeric network and a

Abstract: Methods of catalyzing chemical reactions are provided. A tertiary amine blocked with an acid, the acid having a vapor pressure greater than 1.0 mm Hg at 25° C., is added as a catalyst to reaction mixtures. Reaction mixtures contain uretdione or isocyanate functional materials, in various combinations with hydroxyl, thiol, and/or amine functional materials. Curable compositions comprising these catalysts and reaction mixtures are also provided.

Abstract: The present invention aims to provide a polyester polyol having favorable reactivity and a favorable color tone, which can be used for obtaining a polyurethane having an excellent balance of flexibility, mechanical strength, and chemical resistance, and a method for producing the polyester polyol. The object can be achieved with a polyester polyol in which an aliphatic diol contains as a structural unit 1,10-decanediol derived from a biomass resource, and in which the aldehyde body content in the polyester polyol is 0.01 to 0.5% by weight, and a method for producing the polyester polyol.

Abstract: The invention relates to a process for the production of polybutadienols from polybutadienes with number-average molar mass from 300 to 2000 g/mol comprising from 20 to 50% of 1,4 double bonds and from 50 to 80% of 1,2 vinylic and 1,2 cyclovinylic double bonds, based on the quantity of all of the double bonds, comprising the steps of i) epoxidation of some or all of the 1,4 double bonds with an epoxidizing reagent which selectively epoxidizes 1,4 double bonds, ii) reaction of the epoxidized polybutadiene with an alcohol or water to give a polybutadienol.

Abstract: The present invention relates to aqueous peptide-functionalized polyurethane dispersions that can be used as adhesives, in particular for metal surfaces, such as steel surfaces. As hybrid materials, they provide for a versatile system that can be finely tuned and combine the advantageous properties of polyurethane and peptide materials. Also encompassed are processes for their production, compositions containing them and their use as coatings and adhesives.

Abstract: The present teachings contemplate a method that includes a step of providing a first amount of esterified reaction product of an acid and an epoxy-based material. The esterified reaction product may be further reacted an epoxy resin to form a polymeric epoxy.

Abstract: The present invention relates to bio-copolyester of polyethylene terephthalate composition prepared from raw materials which are derived from biomass. The bio-composition comprises: 1) about 92 to about 99 mole % of bioPET, prepared from bioMEG and bioPTA, 2) about 1 to about 8 mole % bio-based acids, bio-based diols and/or bio-based branching agents. Bio-based acids include bio-aliphatic diacids or bio-aromatic diacids, or their corresponding bio-esters, or a mixture thereof. Bio-based diols include bio-aliphatic diol comprising 3 to 20 carbon atoms, bio-cycloaliphatic diol of 6 to 20 carbon atoms, or bio-aromatic diol comprising 6 to 14 carbon atoms, or a mixture thereof. Bio-based branching agents include bio-aliphatic compounds having more than two functionalities such as bio-trimellitic anhydride, bio-trimethylol propane, or bio-pentaerythritol, or a blend thereof.